Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.

Inclusion Criteria:

• Diagnosed with diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma or transformed follicular lymphoma
• Scheduled to receive commercial axi-cel at Moffitt Cancer Center
• Able to speak and read standard english
• Have no documented or observable psychiatric or neurological diagnoses that interfere with study participation (e.g., schizophrenia)
• Have no history of traumatic brain injury, stroke, or dementia
• Able to provide informed consent